003 PH Travocort e-Brochure

Isoconazole nitrate +




Diflucortolone valerate





Travocort ®



Anti-fungal / Corticosteroid

Isoconazole nitrate +




Diflucortolone valerate





Travocort ®



Anti-fungal / Corticosteroid

Travocort has broad spectrum anti-fungal
®



activity 1-4
















































Fungal skin infections frequently combine with inflammatory symptoms 3,5




























Data from multicenter study of 525 patients with inflammatory skin mycoses treated in 12
clinical centres across Germany. Based on data from Schropl F. 1981 5
5






References 1. Havlickova B & Friedrich M. Mycoses 2008;51(Suppl 4): 16-26. 2. Oyeka CA & Gugnani HC. Mycopathologia 1990; 110(3):157-161. 3. Veraldi S. Mycoses 2013;56(Suppl 1):3-15.
4. Kessler HJ, et al. Arzneimittelforschung 1979;29:1344-1351. 5. Schropl F Travocort®/Travogen® Cream. Workshop Results, June 15, 1979. Amsterdam: Excerpta Medica, 1981.

Travocort has broad spectrum anti-fungal
®



activity 1-4
















































Fungal skin infections frequently combine with inflammatory symptoms 3,5




























Data from multicenter study of 525 patients with inflammatory skin mycoses treated in 12
clinical centres across Germany. Based on data from Schropl F. 1981 5
5






References 1. Havlickova B & Friedrich M. Mycoses 2008;51(Suppl 4): 16-26. 2. Oyeka CA & Gugnani HC. Mycopathologia 1990; 110(3):157-161. 3. Veraldi S. Mycoses 2013;56(Suppl 1):3-15.
4. Kessler HJ, et al. Arzneimittelforschung 1979;29:1344-1351. 5. Schropl F Travocort®/Travogen® Cream. Workshop Results, June 15, 1979. Amsterdam: Excerpta Medica, 1981.

Travocort dual action offers synergistic
®



activity against fungal skin infections 1


















































Exerts broad spectrum Achieves rapid
Exerts broad spectrum
Achieves rapid
anti-fungal activity, 1-4 improvement in pruritus and
1-4
anti-fungal activity,
improvement in pruritus and
involving the disruption o erythema, with superior
involving the disruption f
erythema, with superior
the fungal cell wall
response rates to
of the fungal cell wall responses rates to
1,3
membrane
membrane 1-3 isoconazole monotherapy 7 6
isoconazole monotherapy
In the fight against fungal skin infections, why settle for one weapon


when you can have Travocort ®














References 1. Havlickova B & Friedrich M. Mycoses 2008;51(Suppl 4): 16-26. 2. Oyeka CA & Gugnani HC. Mycopathologia 1990; 110(3):157-161. 3. Veraldi S. Mycoses 2013;56(Suppl 1):3-15.
4. Kessler HJ, et al. Arzneimittelforschung 1979;29:1344-1351. 5. Tauber U. Mykosen 1979;22(7):223-232. 6. Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70-e73.

Travocort dual action offers synergistic
®



activity against fungal skin infections 1


















































Exerts broad spectrum Achieves rapid
Exerts broad spectrum
Achieves rapid
anti-fungal activity, 1-4 improvement in pruritus and
1-4
anti-fungal activity,
improvement in pruritus and
involving the disruption o erythema, with superior
involving the disruption f
erythema, with superior
the fungal cell wall
response rates to
of the fungal cell wall responses rates to
1,3
membrane
membrane 1-3 isoconazole monotherapy 7 6
isoconazole monotherapy
In the fight against fungal skin infections, why settle for one weapon


when you can have Travocort ®














References 1. Havlickova B & Friedrich M. Mycoses 2008;51(Suppl 4): 16-26. 2. Oyeka CA & Gugnani HC. Mycopathologia 1990; 110(3):157-161. 3. Veraldi S. Mycoses 2013;56(Suppl 1):3-15.
4. Kessler HJ, et al. Arzneimittelforschung 1979;29:1344-1351. 5. Tauber U. Mykosen 1979;22(7):223-232. 6. Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70-e73.

Travocort offers RAPID RELIEF OF PRURITUS
®



compared with isoconazole monotherapy













1% isoconazole nitrate + 0.1%

1% isoconazole nitrate diflucortolone valerate

Proportion of patients with pruritus
100 100





80 80





60 60





40 40






20 20





0 0

Baseline Week 1 Week 2 Week 3 Baseline Week 1 Week 2 Week 3





None (Score 0) Slight (Score 1) Moderate (Score 2) Severe (Score 3)


Retrospective study of patients with inflammatory tinea inguinalis treated with 1%

isoconazole nitrate (n=31) or 1% isoconazole nitrate + 0.1% diflucortolone valerate (n=27).














Reference: Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70 e73.

Travocort offers RAPID RELIEF OF PRURITUS
®



compared with isoconazole monotherapy













1% isoconazole nitrate + 0.1%

1% isoconazole nitrate diflucortolone valerate

Proportion of patients with pruritus
100 100





80 80





60 60





40 40






20 20





0 0

Baseline Week 1 Week 2 Week 3 Baseline Week 1 Week 2 Week 3





None (Score 0) Slight (Score 1) Moderate (Score 2) Severe (Score 3)


Retrospective study of patients with inflammatory tinea inguinalis treated with 1%

isoconazole nitrate (n=31) or 1% isoconazole nitrate + 0.1% diflucortolone valerate (n=27).














Reference: Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70 e73.

Travocort offers RAPID RELIEF OF [ERYTHEMA]
®



compared with isoconazole monotherapy













1% isoconazole nitrate + 0.1%

1% isoconazole nitrate diflucortolone valerate
Proportion of patients with [erythema]
100 100





80 80





60 60





40 40






20 20





0 0

Baseline Week 1 Week 2 Week 3 Baseline Week 1 Week 2 Week 3




None (Score 0) Slight (Score 1) Moderate (Score 2) Severe (Score 3)



Retrospective study of patients with inflammatory tinea inguinalis treated with 1%

isoconazole nitrate (n=31) or 1% isoconazole nitrate + 0.1% diflucortolone valerate (n=27).















Reference: Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70 e73.

Travocort offers RAPID RELIEF OF [ERYTHEMA]
®



compared with isoconazole monotherapy













1% isoconazole nitrate + 0.1%

1% isoconazole nitrate diflucortolone valerate
Proportion of patients with [erythema]
100 100





80 80





60 60





40 40






20 20





0 0

Baseline Week 1 Week 2 Week 3 Baseline Week 1 Week 2 Week 3




None (Score 0) Slight (Score 1) Moderate (Score 2) Severe (Score 3)



Retrospective study of patients with inflammatory tinea inguinalis treated with 1%

isoconazole nitrate (n=31) or 1% isoconazole nitrate + 0.1% diflucortolone valerate (n=27).















Reference: Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70 e73.

Travocort dual action:
®



Working together towards relief








®
Travocort has a well-established, acceptable safety profile 2,4,6


• Associated with low systemic absorption of its active

ingredients 6





®
• The corticosteroid component of Travocort has a low

potential to induce atrophy and telangiectasia 6




• Evidence from 40 years’ experience and numerous


®
clinical trials demonstrate that Travocort is well

tolerated 2









Travocort ®


• A combination treatment offering dual

action against inflammation and fungal skin Isoconazole nitrate +

infections 1-3 Diflucortolone valerate



• Superior clinical results compared to

treatment with isoconazole monotherapy 2 Travocort ®

Anti-fungal / Corticosteroid
• Rapid relief from inflammatory symptoms,

including itch 5









References 1. Havlickova B & Friedrich M. Mycoses 2008;51(Suppl 4): 16-26. 2. Veraldi S. Mycoses 2013;56(Suppl 1):3-15. 3. Schropl F Travocort®/Travogen® Cream. Workshop Results, June 15, 1979.
Amsterdam: Excerpta Medica, 1981. 4. Tauber U. Mykosen 1979;22(7):223-232 5. Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70-e73. 6. Frosch PJ, et al. Br J Dermatol 1981;104(1):57-65

Travocort dual action:
®



Working together towards relief








®
Travocort has a well-established, acceptable safety profile 2,4,6


• Associated with low systemic absorption of its active

ingredients 6





®
• The corticosteroid component of Travocort has a low

potential to induce atrophy and telangiectasia 6




• Evidence from 40 years’ experience and numerous


®
clinical trials demonstrate that Travocort is well

tolerated 2









Travocort ®


• A combination treatment offering dual

action against inflammation and fungal skin Isoconazole nitrate +

infections 1-3 Diflucortolone valerate



• Superior clinical results compared to

treatment with isoconazole monotherapy 2 Travocort ®

Anti-fungal / Corticosteroid
• Rapid relief from inflammatory symptoms,

including itch 5









References 1. Havlickova B & Friedrich M. Mycoses 2008;51(Suppl 4): 16-26. 2. Veraldi S. Mycoses 2013;56(Suppl 1):3-15. 3. Schropl F Travocort®/Travogen® Cream. Workshop Results, June 15, 1979.
Amsterdam: Excerpta Medica, 1981. 4. Tauber U. Mykosen 1979;22(7):223-232 5. Veraldi S, et al. J Drugs Dermatol 2012;11(11)e70-e73. 6. Frosch PJ, et al. Br J Dermatol 1981;104(1):57-65

Abbreviated Product Information






COMPOSITION: 1g Isoconazole nitrate + Diflucortolone valerate (Travocort®) contains 10 mg (1 %) isoconazole
nitrate and 1 mg (0.1 %) diflucortolone valerate. INDICATIONS: Initial or interim treatment of those superficial fungal

infections of the skin which are accompanied by highly inflammatory or eczematous skin conditions. POSOLOGY

AND METHOD OF ADMINISTRATION: Cutaneous use. Travocort® should be applied twice daily to the diseased
areas of skin. The treatment with Travocort® must be terminated after regression of the inflammatory or

eczematous skin condition, at the latest, however, after 2 weeks, and the therapy continued or followed up with a

glucocorticoid free anti-fungal preparation. CONTRAINDICATIONS: Tuberculous or syphilitic processes in the area
to be treated, virus diseases, rosacea, perioral dermatitis and postvaccination skin reactions in the area to be

treated. Hypersensitivity to the active substances or to any of the excipients. UNDESIRABLE EFFECTS: The common

adverse effects of topically applied Travocort® cream include application site burning and irritation. SHELF LIFE: 36
months. SPECIAL PRECAUTIONS FOR STORAGE: Store at temperatures not exceeding 30°C.



®
Travocort Cream API version SEP2019















LEO Pharma Philippines



For Healthcare Professionals Only
A Division of Getz Bros. Philippines, Inc. Full prescribing information available upon request.

th
th
Unit 9E, 9 Floor, Inoza Tower, 40 St., You may unsubscribe to this service by sending an email to [email protected]
© LEO PHARMA 2020. ALL TRADEMARKS MENTIONED BELONG TO THE LEO PHARMA GROUP.
Bonifacio Global City, Taguig MAT-37335 Valid until 08/11/2022

Abbreviated Product Information






COMPOSITION: 1g Isoconazole nitrate + Diflucortolone valerate (Travocort®) contains 10 mg (1 %) isoconazole
nitrate and 1 mg (0.1 %) diflucortolone valerate. INDICATIONS: Initial or interim treatment of those superficial fungal

infections of the skin which are accompanied by highly inflammatory or eczematous skin conditions. POSOLOGY

AND METHOD OF ADMINISTRATION: Cutaneous use. Travocort® should be applied twice daily to the diseased
areas of skin. The treatment with Travocort® must be terminated after regression of the inflammatory or

eczematous skin condition, at the latest, however, after 2 weeks, and the therapy continued or followed up with a

glucocorticoid free anti-fungal preparation. CONTRAINDICATIONS: Tuberculous or syphilitic processes in the area
to be treated, virus diseases, rosacea, perioral dermatitis and postvaccination skin reactions in the area to be

treated. Hypersensitivity to the active substances or to any of the excipients. UNDESIRABLE EFFECTS: The common

adverse effects of topically applied Travocort® cream include application site burning and irritation. SHELF LIFE: 36
months. SPECIAL PRECAUTIONS FOR STORAGE: Store at temperatures not exceeding 30°C.



®
Travocort Cream API version SEP2019















LEO Pharma Philippines



For Healthcare Professionals Only
A Division of Getz Bros. Philippines, Inc. Full prescribing information available upon request.

th
th
Unit 9E, 9 Floor, Inoza Tower, 40 St., You may unsubscribe to this service by sending an email to [email protected]
© LEO PHARMA 2020. ALL TRADEMARKS MENTIONED BELONG TO THE LEO PHARMA GROUP.
Bonifacio Global City, Taguig MAT-37335 Valid until 08/11/2022

Approval Signatures




Name: PH Travocort® e-Brochure

Id: MAT-37335

Version: 1

Status: Approved


Product: Travocort®

Form:

Strength:

Region/Country: Philippines

Target Audience: Healthcare Professionals (HCPs)


Description: PH Travocort® e-Brochure for HCPs





Document Approvals

Regulatory and Trademark - 12-Aug-2020 05:00:20
Ee Me Khoo (KEMSG)
GMT+0000

Scientific/Medical Affairs - 12-Aug-2020 05:01:31
Arby Valeriano (AYVPH)
GMT+0000
Frances Angela Tungol (FRCSG) Sales & Marketing - 12-Aug-2020 07:21:45 GMT+0000

Ee Me Khoo (KEMSG) Final - 12-Aug-2020 07:25:34 GMT+0000